Anti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients

Journal of Pediatric Gastroenterology and Nutrition

Volumn 34, Issue 4, 2002, Pages 389-393

  Serinet, Marie Odile ^a   Jacquemin, Emmanuel ^a   Habes, Dalila ^a   Debray, Dominique ^a   Fabre, Monique ^a   Bernard, Olivier ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Children; Epstein Barr virus; Liver transplantation; Lymphoproliferative disease; Rituximab

Indexed keywords

CD20 ANTIGEN; CYCLOSPORIN A; IMMUNOGLOBULIN; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CHILD; CLINICAL ARTICLE; DRUG INDUCED DISEASE; EPSTEIN BARR VIRUS; GRAFT REJECTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIVER TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR REGRESSION; VIRUS GENOME; VIRUS LOAD;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; INFANT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS;

HUMAN HERPESVIRUS 4;

EID: 0036260310     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200204000-00014     Document Type: Article

References (19)

1. Epstein-Barr virus serology and Epstein-Barr virus associated lymphoproliferative disorders in pediatric liver transplant recipients
2. Overview of posttransplant B-cell lymphoproliferative disorders
3. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy
4. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation
5. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
6. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation
7. Anti-B cell antibodies for the treatment of monoclonal Epstein-Barr virus-induced lymphoproliferative syndrome after multivisceral transplantation
8. Anti-B-cell monoclonal antibody in treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
9. Humanized anti-CD20 monoclonal antibody (rituximab) in posttransplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
10. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: A report of three cases
11. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: A new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?
12. Treatment of posttransplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
13. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
14. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders
15. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody
16. Terminology for hepatic allograft rejection
17. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients
18. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease
19. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response